

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

PANASCI ET AL.

Examiner: James D. Anderson

APPLICATION NO: 10/534,573

FILED: MAY 11, 2005

FOR: COMBINATION OF A NITROGEN MUSTARD ANALOGUE AND
IMATINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC
LEUKEMIA

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the restriction requirement under 35 USC 121 and 372 dated April 9, 2008, Applicants elect Group I, claims 1-7 and 10-11, and select clorambucil as the single disclosed nitrogen mustard analogue. All claims read on the elected species.

Entry of this response is requested and an action on the merits awaited.

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Date: May 8, 2008